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Felice Pepe,1 Christopher J. Walker,1 Allison E. Walker,1 Andrew J. Carroll,6 Jessica Kohlschmidt,1,3 Ann-Kathrin Eisfeld,1 Bayard L. Powell,7
Geoffrey L. Uy,8 Jonathan E. Kolitz,9 Eunice S. Wang,10 Sakari Kauppinen,5 Adrienne Dorrance,1 Richard M. Stone,11 John C. Byrd,1
Clara D. Bloomfield,1,† and Ramiro Garzon1,†
1The Ohio State University Comprehensive Cancer Center, Columbus, OH; 2Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara,
Italy; 3Alliance Statistics and Data Center, The Ohio State University, Columbus, OH; 4Centre of New Technologies, University of Warsaw, Warsaw, Poland; 5Center for RNA
Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; 6Department of Genetics, University of Alabama at Birmingham, Birmingham, AL; 7The
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC; 8Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO; 9Monter
Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY; 10Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; and 11Dana-Farber Cancer
Institute, Harvard University, Boston, MA
Key Points
•Distinctive circRNA
expression profiles are
associated with
recurrent mutations
and clinical features of
CN-AML patients.
• Individual circRNAs are
associated with
outcome and are
functionally relevant in
CN-AML.
Circular RNAs (circRNAs) are noncoding RNA molecules that display a perturbed
arrangement of exons, called backsplicing. To examine the prognostic and biologic
significance of circRNA expression in cytogenetically normal acute myeloid leukemia
(CN-AML), we conducted whole-transcriptome profiling in 365 younger adults (age 18-
60 years) with CN-AML. We applied a novel pipeline, called Massive Scan for circRNA, to
identify and quantify circRNA expression. We validated the high sensitivity and specificity
of our pipeline by performing RNase R treatment and RNA sequencing in samples of AML
patients and cell lines. Unsupervised clustering analyses identified 3 distinct circRNA
expression–based clusters with different frequencies of clinical and molecular features.
After dividing our cohort into training and validation data sets, we identified 4 circRNAs
(circCFLAR, circKLHL8, circSMC1A, and circFCHO2) that were prognostic in both data sets;
high expression of each prognostic circRNAwas associated with longer disease-free, overall,
and event-free survival. In multivariable analyses, high circKLHL8 and high circFCHO2
expression were independently associated with better clinical outcome of CN-AML patients,
after adjusting for other covariates. To examine the biologic relevance of circRNA
expression, we performed knockdown screening experiments in a subset of prognostic and
gene mutation–related candidate circRNAs. We identified circFBXW7, but not its linear
messenger RNA, as a regulator of the proliferative capacity of AML blasts. In summary, our
findings underscore the molecular associations, prognostic significance, and functional
relevance of circRNA expression in CN-AML.
Introduction
Aberrations in the noncoding transcriptome are emerging as important molecular mechanisms that
contribute to cancer pathogenesis.1-3 The advent of next-generation sequencing has enabled the global,
in-depth study of noncoding RNA species and has intensified the interest in their role in health and
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disease. Circular RNAs (circRNAs) are a class of noncoding, single-
stranded RNA molecules that form covalently closed circles and
are characterized by a perturbed arrangement of exons caused
by aberrant splicing (referred to as backsplicing).4 CircRNAs were
first identified almost 5 decades ago in plants, protozoans, and
viruses5-7 and subsequently in mammals.8-10 Additional studies
revealed a number of features that distinguish circRNAs from linear
protein-coding RNA transcripts, such as the lack of 59 or 39 ends,
the lack of polyadenylated tails, and increased stability and
extended half-life.11 Although not yet fully elucidated, the biogenesis
of circRNAs has been shown to depend on the spliceosome
machinery,12-14 the presence of repeat sequences in the genome,9,10
and RNA binding proteins.15-17 The application of total RNA
sequencing (RNA-seq) and novel bioinformatic approaches,
designed to detect backspliced junctions, has uncovered the
expression of a high number of circRNAs in humans, mice,
metazoans, and plants.18 Recent reports have indicated that
circRNAs are produced from ;10% of all expressed genes, that
a subset of them is evolutionarily conserved, and that circRNAs
are often expressed in a tissue-specific manner.4,19,20 Although
initially considered to represent inherent errors of the splicing
process,2,8 recent studies have unraveled the biologic relevance of
circRNAs.21-25
With regard to the functional significance of circRNAs, recent
studies have demonstrated that circRNAs can sequester micro-
RNAs (miRs) and inhibit their function. Two examples of such
circRNAs are CDR1as/ciRS-7, which contains repetitive binding
sites that capture miR-7,11,21 and circular SRY, which captures
miR-138.11 Although other circRNAs have been proposed to func-
tion in the same manner,25-28 bioinformatic studies have indicated
that only a small fraction of circular RNAs contain target sequences
for miRs and can function as miR regulators.29,30 CircRNAs have
also been shown to interact with RNA binding proteins or RNA
polymerases and regulate gene transcription.31 In addition, recent
studies have suggested that individual circRNAs can interact with
ribosomes and be translated into peptides.32-36 However, the
functional relevance and mechanism of action of the majority of the
identified circRNAs remain unknown.
In cancer, expression levels of individual circRNAs have been
identified as candidate biomarkers of disease progression.37-39
With regard to acute myeloid leukemia (AML), it was recently
reported that chromosomal translocations, such as t(15;17)/PML-
RARA or t(9;11)/MLLT3-KMT2A, give rise to fusion circRNAs that
contribute to cellular transformation and survival of the leukemic
blasts.40 However, the prognostic and functional significance of
circRNA expression in AML has not been extensively studied in
large patient cohorts. Herein, we performed total RNA-seq in
younger adults (age ,60 years) with de novo cytogenetically
normal AML (CN-AML) and applied a novel bioinformatic algorithm
to identify and quantify circRNAs. Our goals were to determine
whether circRNA expression is associated with clinical and molec-
ular features of CN-AML patients and whether circRNAs have
functional relevance in this disease.
Patients, materials, and methods
Patients
Pretreatment bone marrow (BM) or blood samples were obtained
from 365 younger adult patients (age 17-59 years) with de novo
CN-AML. All analyzed patients were treated with cytarabine/
anthracycline-based frontline chemotherapy on Cancer and
Leukemia Group B (CALGB)/Alliance trials and were alive 30 days
after initiation of treatment. No patient received allogeneic stem
cell transplantation in first complete remission. Details regarding
treatment protocols are provided in the supplemental Data. All
patients were also enrolled onto companion protocols CALGB
8461 (cytogenetic studies), CALGB 9665 (Leukemia Tissue
Bank) and CALGB 20202 (molecular analyses) (registered at
www.clinicaltrials.gov as #NCT00048958 [CALGB 8461],
#NCT00899223 [CALGB 9665] and #NCT00900224 [CALGB
20202]). All patients provided written informed consent, and all
study protocols were in compliance with the Declaration of Helsinki
and approved by institutional review boards.
Cytogenetic and gene mutation analyses
Cytogenetic analyses were performed in CALGB/Alliance-approved
institutional laboratories and results confirmed by central karyotype
review.41 The diagnosis of normal karyotype was based on the
absence of clonal chromosome abnormalities in $20 metaphases
obtained from BM samples subjected to 24- to 48-hour unstimu-
lated cultures.41
Targeted amplicon sequencing using the Miseq platform (Illumina)
was used to analyze DNA samples for the presence of gene
mutations that are established prognosticators in CN-AML (ie,
mutations in the ASXL1,42 DNMT3A [R882 and non-R882],43
IDH1, IDH2 [R140 and R172],44 NPM1,45 RUNX1,46 TET2,47 and
WT1 genes48 and FLT3–tyrosine kinase domain [FLT3-TKD]
mutations49) or that occur recurrently in CN-AML (ie, SF1, SF3A1,
SF3B1, SRSF2, U2AF1, U2AF2, and ZRSR2), as described
previously.50,51 A variant allele frequency of $10% was used as
the cutoff to distinguish between mutated vs wild-type alleles. The
presence of biallelic mutations in the CEBPA gene and FLT3–
internal tandem duplications (FLT3-ITDs) were evaluated using
Sanger sequencing and fragment analysis, respectively, as previously
described.52,53
Transcriptome analyses
RNA samples of all patients (N5 365) were analyzed with RNA-seq
(after depletion of ribosomal and mitochondrial RNA) using the
Illumina HiSeq 2500 platform. Details regarding library genera-
tion protocols and sequencing are provided in the supplemental
Data. To detect and quantify circRNA expression, we used a novel
bioinformatic pipeline, called Massive Scan for circRNAs
(MScircRNA), the features of which are presented in the Results
section and in supplemental Data.
To determine the status of patients (ie, high vs low expressers) with
regard to prognostic expression markers (ie, expression of the
BAALC,54 MN1,55 and ERG56 genes and expression of miR-
181a57 and miR-15558), the median values of normalized RNA-seq
reads were used as the cutoff. With regard to miR-3151,59 patients
expressing this miR were compared with those who did not. Data
from small RNAs (miR-181a, miR-155, and miR-3151) were
obtained using small RNA-seq.
Statistical analyses
Clinical end point definitions are given in the supplemental Data.
Baseline demographic, clinical, and molecular features were com-
pared between the training and validation sets, circRNA-expression
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based clusters, and low and high circRNA expressers using the
Kruskal-Wallis and Fisher’s exact tests for continuous and categor-
ical variables, respectively. The estimated probabilities of disease-
free (DFS) and overall survival (OS) were calculated using the
Kaplan-Meier method, and the log-rank test evaluated differences
between survival distributions. Cox proportional hazards models
were used to calculate hazard ratios (HRs) for DFS, OS, and event-
free survival (EFS). Multivariable proportional hazards models were
constructed for DFS, OS, and EFS using a backward selection
procedure.60 Variables significant at a 5 0.20 from the univariable
analyses were considered for multivariable analyses (supplemental
Data provides variables considered in model inclusion). For the
time-to-event end points, the proportional hazards assumption was
checked for each variable individually. All statistical analyses were
performed by the Alliance Statistics and Data Center using SAS
9.4 and TIBCO Spotfire S1 8.2 software. For laboratory in vitro
experiments, 2-tailed Student t tests were performed. P , .05 was
considered significant.
Results
MScircRNA: a novel pipeline for the detection and
quantification of circular RNAs
To detect and quantify bona fide circRNAs, we developed a novel
computational method called MScircRNA. As a starting point,
we assembled a list with all backsplicing events detectable in our
RNA-seq data set. The list was further filtered for backsplicing
events compatible with perturbed arrangement of exons of the
same gene. We compiled a FASTA file containing the sequences of
the putative backsplicing junctions, as well as those annotated in
the circBase database61 (supplemental Table 1). To quantify the
expression levels of the detected circRNAs, we removed all linear
reads and aligned the remaining reads to the curated list of candi-
date circRNA sequences. Fragments per kilobase pair of transcript
per million mapped reads (FPKMs) were obtained by normalizing
the fragment counts against the sequencing space across the
backsplicing junction (supplemental Figure 1). Additional details
regarding MScircRNA are provided in the supplemental Data.
Biochemical validation of the MScircRNA pipeline
To experimentally test our novel pipeline, we performed a sequenc-
ing experiment using samples from 7 CN-AML patients and 3 AML
cell lines (Eol-1, OCI-AML3, and K-562) that were either mock-
treated or treated with the RNase R exonuclease. RNase R prefer-
entially degrades linear transcripts but has minimal effect on
circularized transcripts and can therefore be used to differentiate
between true circular RNAs and sequencing artifacts.62,63
We generated circRNA profiles of the mock and RNase R–treated
samples using MScircRNA and identified 3031 circRNAs that were
robustly expressed (FPKMs $1) in the 10 samples (supplemental
Table 2). We found that RNase R treatment led to a significant
FPKM increase for 2380 (78.5%) of the 3031 predicted circRNAs
with respect to the untreated samples. Only 1 candidate circRNA
(SNORD10) had significantly lower FPKMs in RNase R–treated
AML samples (,0.01%). Regarding the remaining 650 circRNAs in
which difference in expression between the 2 groups did not reach
statistical significance, the trend was still that of enrichment
because of resistance to RNase R for all except 10 circRNAs (10
[1.5%] of 650). Finally, in the case of 2323 circRNAs for which
a related linear transcript could be detected and quantified, we
calculated the ratio of the circular transcript FPKMs to the total
FPKMs for the gene (circular FPKMs1 linear FPKMs; ie, the circular
fraction [CF]). It was recently proposed that the CF can be used
as a parameter to distinguish circRNAs with functional signifi-
cance from transcriptional noise.30 We found that for 2321 of
these circRNAs, RNase R treatment increased the calculated
CF (supplemental Table 3; supplemental Figure 2A-B). These
results indicate that a vast majority of the circRNAs identified by
MScircRNA were true circularized RNA transcripts and not artifacts
of sequencing.
Circular RNA expression in AML and association with
host linear gene expression
To study the prognostic and biologic significance of circRNA
expression in CN-AML, we conducted analyses in a cohort of 365
younger CN-AML patients using MScircRNA (Table 1 lists the
patients’ clinical features; supplemental Table 4 lists the RNA-seq
characteristics). First, we detected and measured a total of 34 269
candidate circRNAs. To focus on the circular transcripts that were
robustly and differentially expressed among the CN-AML samples,
we applied stringent criteria. We retained the circRNAs, which were
expressed above a threshold level (FPKM $1) and displayed
variance of at least a 1.5-fold change in either direction from their
corresponding median expression value. Additionally, we selected
the circRNAs that had a CF .0.1 (which is the CF ratio threshold
proposed to detect bona fide true circRNAs).30 These combined
filters yielded a curated list of 180 circRNAs that were used in
additional analyses (supplemental Table 5).
Associations between circRNA expression and
molecular features of CN-AML patients
To examine whether distinctive patterns of circRNA expression
were present in the data set of younger adults with CN-AML, we
performed unsupervised clustering analysis. Specifically, we used
a consensus nonnegative matrix factorization method to evaluate
the segregation of the patients in circRNA-based clusters, according
to circular expression. Cophenetic correlation coefficients indicated
that the separation of patients into 3 distinct clusters generated the
most robust consensus clustering (Figure 1A). Cluster 1 consisted
of 115 patients, cluster 2 of 106, and cluster 3 of 144 (Figure 1B).
Overall, there were significant differences with regard to the
distribution of clinical and molecular features among patients in the
3 circRNA-based clusters. Patients in cluster 1 were older than
patients in clusters 2 and 3 (P 5 .02). Furthermore, cluster 1
patients had higher white blood cell (P , .001) and platelet counts
(P, .001) but lower percentages of blasts in blood (P, .001) than
patients in the other 2 clusters. Patients in cluster 1 were also more
likely to present with extramedullary manifestations of their disease
(P 5 .005). With regard to recurrent prognostic gene mutations,
cluster 3 was enriched for the presence of FLT3-ITD. Concerning
composite genotypes, cluster 3 patients were more likely to harbor
the FLT3-ITD/NPM1–mutated genotype (Figure 1B). Patients in
cluster 1 showed enrichment for NPM1 and DNMT3A mutations.
The FLT3 wild-type/NPM1-mutated genotype was more frequent
in patients in cluster 1. Cluster 2 showed a strong enrichment for
the presence of mutations in transcription factors, such as biallelic
CEBPA and RUNX1 mutations. NPM1 mutations, DNMT3A
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Table 1. Clinical and molecular features of younger adult patients
with cytogenetically normal AML (N 5 365)
Characteristic Summary statistics
Age, y
Median 46
Range 17-59
Sex, n (%)
Male 188 (52)
Female 177 (48)
Race, n (%)
White 324 (91)
Nonwhite 34 (9)
Hemoglobin, g/dL
Median 9.2
Range 4.2-25.1
Platelet count, 3109/L
Median 56
Range 8-445
WBC count, 3109/L
Median 28.8
Range 0.6-475.0
Blood blasts, %
Median 60
Range 0-97
BM blasts, %
Median 68
Range 18-96
Extramedullary involvement, n (%)
Present 106 (30)
Absent 250 (70)
ASXL1, n (%)
Mutated 12 (3)
Wild type 334 (97)
CEBPA, n (%)
Double mutated 54 (16)
Wild type 294 (84)
DNMT3A, n (%)
Mutated 139 (39)
R882 105
Non-R882 34
Wild type 213 (61)
FLT3-ITD, n (%)
Present 137 (38)
Absent 221 (62)
FLT3-TKD, n (%)
Present 36 (10)
Absent 314 (90)
IDH1, n (%)
Mutated 27 (8)
Wild type 325 (92)
Table 1. (continued)
Characteristic Summary statistics
IDH2, n (%)
Mutated 34 (10)
Wild type 318 (90)
NPM1, n (%)
Mutated 201 (58)
Wild type 143 (42)
RUNX1, n (%)
Mutated 19 (5)
Wild type 333 (95)
SF1, n (%)
Mutated 2 (1)
Wild type 350 (99)
SF3A1, n (%)
Mutated 1 (0)
Wild type 351 (100)
SF3B1, n (%)
Mutated 10 (3)
Wild type 342 (97)
SRSF2, n (%)
Mutated 11 (3)
Wild type 339 (97)
TET2, n (%)
Mutated 40 (11)
Wild type 312 (89)
U2AF1, n (%)
Mutated 4 (1)
Wild type 348 (99)
U2AF2, n (%)
Mutated 0 (0)
Wild type 352 (100)
WT1, n (%)
Mutated 39 (11)
Wild type 313 (89)
ZRSR2, n (%)
Mutated 15 (4)
Wild type 337 (96)
ELN genetic group*, n (%)
Favorable 199 (59)
Intermediate 88 (26)
Adverse 52 (15)
ELN, European LeukemiaNet; WBC, white blood cell count.
*Among patients with CN-AML, the ELN favorable-risk category comprises patients with
double-mutated CEBPA and patients with mutated NPM1 without FLT3-ITD or with FLT3-
ITDlow. The ELN intermediate-risk category includes patients with wild-type or single-mutated
CEBPA, patients with wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow, and/or patients
with mutatedNPM1 and FLT3-ITDhigh. The ELN adverse-risk category comprises patients with
wild-type or single-mutated CEBPA and wild-type NPM1 with FLT3-ITDhigh, patients with
mutated RUNX1 and/or ASXL1 (if these mutations do not co-occur with favorable-risk
subtypes), and/or patients with mutated TP53. FLT3-ITDlow is defined by an FLT3-ITD/FLT3
wild-type allelic ratio of ,0.5, and FLT3-ITDhigh is defined by an FLT3-ITD/FLT3 wild-type
allelic ratio of $0.5.
†The median expression value was used as a cut point.
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mutations, and FLT3-ITD were markedly underrepresented in
cluster 2 (Table 2; Figure 1B).
The patients in the circRNA clusters also showed notable differ-
ences in expression levels of messenger RNAs (mRNAs) and miRs
prognostic in CN-AML. Patients in cluster 3 were more frequently
high expressers of ERG and miR-155, and those in cluster 2 of ERG
BAALC, MN1, miR-181a, and miR-3151. In contrast, patients with
low expression of prognostic mRNAs and miRNAs were signifi-
cantly overrepresented in cluster 1 (Table 2; Figure 1B).
Prognostic significance of circRNA expression in
younger adults with CN-AML
To evaluate the prognostic significance of circRNA expression in
CN-AML, we randomly divided our cohort of younger CN-AML
patients into a training set, used for exploratory analysis (n 5 254),
and a validation set (n5 111). There were no significant differences
in clinical and molecular features between the 2 groups, except for
percentages of blasts in blood (higher in training set patients;
P 5 .03), frequency of FLT3-TKD mutations (more frequent in the
training set; P 5 .02), and ERG (P 5 .01) and BAALC (P 5 .002)
expression levels (for both genes, training set patients were more
frequently high expressers; supplemental Table 6).
Next, we evaluated the association of circRNA expression with EFS
in the training set using univariate Cox regression. EFS was chosen
because it is a composite outcome end point that comprehen-
sively evaluates response to chemotherapy, probability of relapse,
and probability of survival. Twelve circRNAs were found to
be significantly associated with EFS in the training set (threshold
P , .05; supplemental Table 7). Four of these 12 circRNAs were
also significantly associated with clinical outcome in the validation
data set (circCFLAR, circKLHL8, circSMC1A, and circFCHO2).
circKLHL8 and circSMC1A showed the strongest association with
clinical outcome; patients with high circKLHL8 expression had
longer DFS, OS, and EFS than patients with low circKLHL8
expression (P , .001 for all 3 end points; Figure 2A-C). Patients
with high circSMC1A had longer DFS (P 5 .002), OS (P 5 .004),
and EFS (P 5 .02) than patients with low circSMC1A expression
(Figure 2D-F). Similarly, patients with either high circFCHO2
expression or high circCFLAR expression had better outcomes
than those of patients with low circFCHO2 or circCFLAR
expression, respectively (supplemental Figure 3A-F). We did not
detect an association between circRNA expression and complete
remission rates in either of the data sets (data not shown).
Validation of the prognostic circRNA expression
status of CN-AML
Before further studying the circRNAs, which were found to be
associated with clinical outcome of younger adult CN-AML patients,
we sought to validate our circRNA expression measurements and
the distinction of patients in high vs low expressers with additional
transcriptome profiling methods. To this end, we designed real-time
quantitative polymerase chain reaction (RT-qPCR) assays that
target the backsplicing regions of circRNA transcripts and can
quantify their expression levels. We then measured circRNA
expression in subsets of patients who had been classified as high
or low expressers of the respective prognostic circRNAs based on
MScircRNA analysis. There was overall high concordance between
the MScircRNA and RT-PCR measurements in these patients, as
indicated by the Pearson’s correlation coefficient values (Pearson’s
r, 0.94-0.99; supplemental Figure 4A-D).
Associations of prognostic circRNAs and
pretreatment clinical and molecular features of
CN-AML patients
Next, we investigated whether the expression of the prognostic
circRNAs in CN-AML patients were associated with distinctive
clinical or molecular features. Patients with high circKLHL8 expres-
sion had higher platelet counts (P 5 .05) and lower percentages of
blasts in blood (P 5 .002) and BM (P 5 .05) than patients with low
circKLHL8 expression (supplemental Table 8). High circKLHL8
expressers were also more likely to have FLT3-TKD (P 5 .05)
and less likely to have FLT3-ITD (P , .001) or high expression of
miR-155 (P , .001) or ERG (P , .001; supplemental Table 8).
Patients with high circSMC1A were more likely to be female
(P 5 .002) and less likely to have FLT3-ITD (P 5 .04) than patients
Table 1. (continued)
Characteristic Summary statistics
NPM1 and DNMT3A, n (%)
Either or neither mutated 239 (69)
Both mutated 105 (31)
NPM1 and FLT3-ITD, n (%)
Either or neither mutated 252 (74)
Both mutated 89 (26)
ERG expression group†, n (%)
High 184 (51)
Low 178 (49)
BAALC expression group†, n (%)
High 168 (50)
Low 166 (50)
MN1 expression group†, n (%)
High 176 (50)
Low 173 (50)
miR-181a expression group†, n (%)
High 148 (50)
Low 147 (50)
miR-3151, n (%)
Expressed 51 (17)
Not expressed 244 (83)
miR-155 expression group†, n (%)
High 147 (50)
Low 148 (50)
ELN, European LeukemiaNet; WBC, white blood cell count.
*Among patients with CN-AML, the ELN favorable-risk category comprises patients with
double-mutated CEBPA and patients with mutated NPM1 without FLT3-ITD or with FLT3-
ITDlow. The ELN intermediate-risk category includes patients with wild-type or single-
mutated CEBPA, patients with wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow, and/
or patients with mutated NPM1 and FLT3-ITDhigh. The ELN adverse-risk category
comprises patients with wild-type or single-mutated CEBPA and wild-type NPM1 with
FLT3-ITDhigh, patients with mutated RUNX1 and/or ASXL1 (if these mutations do not co-
occur with favorable-risk subtypes), and/or patients with mutated TP53. FLT3-ITDlow is
defined by an FLT3-ITD/FLT3 wild-type allelic ratio of ,0.5, and FLT3-ITDhigh is defined by
an FLT3-ITD/FLT3 wild-type allelic ratio of $0.5.
†The median expression value was used as a cut point.
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with low circSMC1A expression (supplemental Table 9). The
clinical and molecular features associated with high expression of
circCFLAR and circFCHO2 are provided in supplemental Tables
10 and 11, respectively.
Association of prognostic circRNA expression with
corresponding linear transcripts
To ensure that our observations on prognostic circRNAs were not
merely reflecting the prognostic significance of the corresponding
linear transcripts, we examined the correlation of circular and linear
RNA expression for the 4 circRNAs with validated prognostic
significance. With the exception of circFCHO2, we found the
correlation between circular and linear transcripts to be weak
(range of Pearson’s r, 20.05 to 0.29). In keeping with these
findings, linear CFLAR, KLHL8, and SMC1A mRNAs were not
prognostic in the validation set of younger adults with CN-AML. In
contrast, circFCHO2 and linear FCHO2 were moderately corre-
lated in the validation set (Pearson’s r, 0.69). High linear FCHO2
expression also was associated with better clinical outcome and
longer DFS, although not as strongly as circFCHO2 expression
(supplemental Figure 5A-L).
Multivariable analyses
To evaluate the prognostic significance of circRNAs in the context
of established prognostic markers, we constructed multivariable
models, concomitantly analyzing expression of the 4 prognostic
circRNAs. With regard to DFS, high circKLHL8 expression
remained significantly associated with longer DFS (HR, 0.53;
P 5 .02) after adjusting for presence of FLT3-ITD and MN1
expression status. High circKLHL8 (HR, 0.53; P 5 .01) and high
circFCHO2 (HR, 0.45; P5 .002) were significantly associated with
longer OS after adjusting for MN1 expression status. Finally, high
circKLHL8 and high circFCHO2 expression were significantly
associated with longer EFS (HR, 0.46; P 5 .002 and HR, 0.56;
P 5 .02, respectively) after adjusting for the presence of DNMT3A
mutations and MN1 expression status (Table 3).
Molecular pathways associated with expression of
prognostic circRNAs
To gain mechanistic insights and detect the molecular pathways
associated with the expression levels of the prognostic circRNAs,
we performed transcriptome and molecular pathway analyses and
compared patients with high with those with low expression of the
prognostic circRNAs.
We found circCFLAR and circKLHL8 expression status to be
associated with a high number of differentially expressed mRNAs
(supplemental Tables 12 and 13, respectively). High circCFLAR
expression was associated with increased abundance of transcripts
involved in intracellular signaling (SGK1 and RGS2) and regulation
of gene expression (SMAD7, KMD7A, and ID2). In pathway
analysis, high circCFLAR expression was found to be associated
with immune system activation, leukocyte chemotaxis, and cytokine
excretion (supplemental Table 14). High circKLHL8was associated
with increased expression of cell cycle, apoptosis, or immune
response regulators (CDKN1, CDKN2, BCL6, and TLR4) as well
as transcription factors involved in macrophage differentiation
(CEBPD and CEBPB). In pathway analysis, high circKLHL8
expression was associated with activation of the differentiation
and apoptosis pathways, as well as with cytokine production and
secretion (supplemental Table 15). CircFCHO2 and circSMC1A
expression were not associated with distinct gene expression
patterns.
Because circRNAs have been shown to function as decoys that
sequester and inhibit the function of miRs, we used an in silico
approach and publicly available databases (miRBase64 and
TargetScan65) to examine whether the prognostic circRNAs
contained miR-binding regions. We did not identify repeat regions
that could function as miR-sequestering sites in the nucleotide
sequence of any of the prognostic circRNAs.
Biologic significance of circRNA expression in AML
To evaluate the biologic significance of circRNA expression in AML,
we performed loss-of-function in vitro experiments focusing on 4
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Figure 1. Unsupervised clustering of CN-AML patients based on expression of circRNAs. (A) Heatmap of circRNA expression in the 3 distinct circRNA expression–
based clusters. Red indicates high and blue low expression. (B) Distribution of prognostic molecular features (ie, gene mutations, gene expression, and miR expression) across
the 3 distinct circRNA expression–based clusters of younger adult patients with CN-AML.
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Table 2. Comparison of clinical and molecular features among 3
distinct, circRNA expression–based clusters of younger adults with
CN-AML
Characteristic
Cluster 1
(n 5 115)
Cluster 2
(n 5 106)
Cluster 3
(n 5 144) P
Age, y .02
Median 50 43 46
Range 19-59 17-59 18-59
Sex, n (%) .06
Male 64 (56) 61 (58) 63 (44)
Female 51 (44) 45 (42) 81 (56)
Race, n (%) .75
White 102 (90) 97 (92) 125 (89)
Nonwhite 11 (10) 8 (8) 15 (11)
Hemoglobin, g/dL .17
Median 9.1 9.5 9.1
Range 4.8-25.1 4.2-13.6 4.9-14.4
Platelet count, 3109/L ,.001
Median 76 51 47
Range 9-433 8-445 8-270
WBC count, 3109/L ,.001
Median 42.8 15.3 29.0
Range 1.9-308.8 0.8-223.8 0.6-475.0
Blood blasts, % ,.001
Median 44 64 68
Range 0-95 0-97 0-97
BM blasts, % .31
Median 70 65 70
Range 18-96 19-95 21-95
Extramedullary involvement, n (%) .005
Present 47 (41) 23 (22) 36 (26)
Absent 67 (59) 80 (78) 103 (74)
ASXL1, n (%) .12
Mutated 1 (1) 6 (6) 5 (4)
Wild type 108 (99) 95 (94) 131 (96)
CEBPA, n (%) ,.001
Double mutated 1 (1) 40 (39) 13 (9)
Wild type 106 (99) 63 (61) 125 (91)
DNMT3A, n (%) ,.001
Mutated 63 (57) 23 (22) 53 (39)
Wild type 48 (43) 81 (78) 84 (61)
FLT3-ITD, n (%) ,.001
Present 36 (32) 19 (19) 82 (57)
Absent 77 (68) 83 (81) 61 (43)
FLT3-TKD, n (%) .02
Present 18 (16) 5 (5) 13 (9)
Absent 77 (68) 83 (81) 61 (43)
IDH1, n (%) .11
Mutated 6 (5) 13 (13) 8 (6)
Wild type 105 (95) 91 (88) 129 (94)
Table 2. (continued)
Characteristic
Cluster 1
(n 5 115)
Cluster 2
(n 5 106)
Cluster 3
(n 5 144) P
IDH2, n (%) .20
Mutated 7 (6) 14 (13) 13 (9)
Wild type 104 (94) 90 (87) 124 (91)
NPM1, n (%) ,.001
Mutated 86 (80) 26 (25) 89 (66)
Wild type 22 (20) 76 (75) 45 (34)
RUNX1, n (%) .03
Mutated 4 (4) 11 (11) 4 (3)
Wild type 107 (96) 93 (89) 133 (97)
SF1, n (%) .52
Mutated 1 (1) 1 (1) 0 (0)
Wild type 110 (99) 103 (99) 137 (100)
SF3A1, n (%) 1.00
Mutated 0 (0) 0 (0) 1 (1)
Wild type 111 (100) 104 (100) 136 (99)
SF3B1, n (%) .32
Mutated 3 (3) 5 (5) 2 (1)
Wild type 108 (97) 99 (95 135 (99)
SRSF2, n (%) .22
Mutated 2 (2) 6 (6) 3 (2)
Wild type 109 (98) 97 (94) 133 (98)
TET2, n (%) .61
Mutated 15 (14) 12 (12) 13 (9)
Wild type 96 (86) 92 (88) 124 (91)
U2AF1, n (%) .11
Mutated 3 (3) 1 (1) 0 (0)
Wild type 108 (97) 103 (99) 137 (100)
U2AF2, n (%) NA*
Mutated 0 (0) 0 (0) 0 (0)
Wild type 111 (100) 104 (100) 137 (100)
WT1, n (%) .007
Mutated 6 (5) 9 (9) 24 (18)
Wild type 105 (95) 95 (91) 113 (82)
ZRSR2, n (%) .85
Mutated 4 (4) 4 (4) 7 (5)
Wild type 107 (96) 100 (96) 130 (95)
ELN genetic group†, n (%) ,.001
Favorable 75 (69) 65 (65) 59 (45)
NA, not applicable.
*P value could not be calculated because of 0 cell counts.
†Among patients with CN-AML, the ELN favorable-risk category comprises patients with
double-mutated CEBPA and patients with mutated NPM1 without FLT3-ITD or with FLT3-
ITDlow. The ELN intermediate-risk category includes patients with wild-type or single-mutated
CEBPA, patients with wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow, and/or patients
with mutatedNPM1 and FLT3-ITDhigh. The ELN adverse-risk category comprises patients with
wild-type or single-mutated CEBPA and wild-type NPM1 with FLT3-ITDhigh, patients with
mutated RUNX1 and/or ASXL1 (if these mutations do not co-occur with favorable-risk
subtypes), and/or patients with mutated TP53. FLT3-ITDlow is defined by an FLT3-ITD/FLT3
wild-type allelic ratio of ,0.5, and FLT3-ITDhigh is defined by an FLT3-ITD/FLT3 wild-type
allelic ratio of equal to or more than 0.5.
‡The median expression value was used as a cut point.
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circRNAs (circPCMTD1, circKLHL8, circCFLAR, and circFBXW7)
that were either prognostic or associated with established,
recurrent gene mutations in this disease. Selection of candidate
circRNAs was also based on our predicted capacity to generate
oligonucleotides that would target the circRNAs without perturbing
the expression of the corresponding linear transcripts. We first
profiled the expression of these 4 circRNAs and the corresponding
linear RNA transcripts with RT-qPCR assays in 2 AML cell lines
(KG-1a and OCI-AML3). In both cell lines, we found that circKLHL8
and circCFLAR represented small fractions of the total amount
of KLHL8 and CFLAR transcripts, whereas circFBXW7 and
circPCMTD1 were expressed at similar or higher levels than linear
PCMTD1 and linear FBXW7, respectively (Figure 3A-B). We
confirmed the circular nature of the transcripts we studied by
demonstrating their resistance to RNase R and the subsequent
increase of the circular/linear transcript ratio upon RNase R
treatment (Figure 3C-D). In addition, we performed PCR experi-
ments using divergent primers that would bind to DNA regions
adjacent to the backsplicing sites of the circRNAs (Figure 3E).
These assays generated amplicons on reverse transcribed RNA
(ie, complementary DNA) but not genomic DNA of KG-1a cells
(Figure 3F; supplemental Table 16). Cloning of the amplicons into
bacterial vectors and Sanger sequencing confirmed the RNAseq-
predicted sequences of the circular transcripts and showed that
they consisted of fused exons.
For the knockdown (KD) experiments, we used RNase H-recruiting
LNA-modified oligonucleotides (gapmers) that specifically targeted
the backsplicing regions of the circRNAs (supplemental Table 17).
Of the 4 tested circRNAs, depletion of circFBXW7 affected the
phenotype of the leukemic cells. More specifically, circFBXW7 KD
led to an increase in the proliferative capacity of KG-1a and OCI-
AML3 cells as measured by WST1 degradation (P , .001 and
P 5 .001, respectively; Figure 3G-H). In addition, cell proliferation
analysis, using BrdU, confirmed an increase in the fraction of
proliferating cells upon depletion of circFBXW7 in both KG-1a and
OCI-AML3 cells (P 5 .01 in both cases; Figure 3I-J). RT-qPCR
showed that the gapmers specifically targeted circFBXW7 without
affecting the expression level of linear FBXW7mRNA (Figure 3K-L).
To further study the functional significance of circFBXW7, we
performed KD experiments in blasts of 3 AML patients. RT-qPCR
confirmed that gapmers also induced specific depletion of
circFBXW7 in the blasts, with no effect on the level of the linear
transcript (Figure 3M). In all 3 patients, circFBXW7 KD generated
a similar phenotype and led to an increase in the number of colonies
formed by the blasts in methylcellulose-based assays (Figure 3N).
To evaluate whether miR sequestration could be the mechanistic
basis of circFBXW7 function, we used a bioinformatics-based
approach and searched the miRBase and TargetScan databases,
as described in “Molecular pathways associated with expression of
prognostic circRNAs.” There were no detectable miR-binding sites
contained within the cirFBXW7 sequence, arguing against an miR-
dependent mechanism of action for this circRNA.
To study the molecular pathways that are associated with the
expression levels of circFBXW7, we performed transcriptome anal-
ysis in high vs low circFBXW7 expressers in our cohort of younger
adults with CN-AML. We found that high expression of circFBXW7
was associated with a distinct gene expression signature and high
expression of genes involved in the regulation of chromatin state
and transcription (HIST1H4F, HIST1H2BG, HISTH2AE, and
MLLT3) as well as key transcription factors and signal transduction
mediators implicated in leukocyte activation and differentiation
(IKZF2, AKT3, and RHOBT3; supplemental Table 18). Low expres-
sion of circFBXW7 was associated with increased expression of
known regulators of stem cell properties, such as multiple Homeobox
genes (HOXA2, HOXA7, HOXA9, HOXB3, and MEIS1) as well as
genes involved in the WNT/b-catenin and NOTCH signaling
pathways (PRICKLE1 and JAG1; supplemental Table 18; sup-
plemental Figure 6). In pathway analysis, high expression of
circFBXW7 was found to be associated with positive regulation of
signal transduction and leukocyte differentiation (supplemental
Table 19). In contrast, decreased expression of circFBXW7 was
associated with the process of hemopoiesis and positive
Table 2. (continued)
Characteristic
Cluster 1
(n 5 115)
Cluster 2
(n 5 106)
Cluster 3
(n 5 144) P
Intermediate 20 (18) 17 (17) 51 (39)
Adverse 14 (13) 18 (18) 20 (15)
NPM1 and DNMT3A, n (%) ,.001
Either or neither mutated 57 (53) 92 (90) 90 (67)
Both mutated 51 (47) 10 (10) 44 (33)
NPM1 and FLT3-ITD, n (%) ,.001
Either or neither mutated 83 (77) 89 (90) 80 (60)
Both mutated 25 (23) 10 (10) 54 (40)
ERG expression group‡, n (%) ,.001
High 14 (12) 75 (71) 95 (66)
Low 100 (88) 30 (29) 48 (34)
BAALC expression group‡, n (%) ,.001
High 15 (16) 85 (82) 68 (51)
Low 81 (84) 19 (18) 66 (49)
MN1 expression group‡, n (%) ,.001
High 29 (27) 77 (76) 70 (50)
Low 79 (73) 24 (24) 70 (50)
miR-181a expression group‡, n (%) ,.001
High 8 (8) 81 (90) 59 (54)
Low 87 (92) 9 (10) 51 (46)
miR-3151 expression group‡, n (%) ,.001
Expressed 3 (3) 36 (40) 12 (11)
Not expressed 92 (97) 54 (60) 98 (89)
miR-155 expression group‡, n (%) ,.001
High 33 (35) 37 (41) 77 (70)
Low 62 (65) 53 (59) 33 (30)
NA, not applicable.
*P value could not be calculated because of 0 cell counts.
†Among patients with CN-AML, the ELN favorable-risk category comprises patients with
double-mutated CEBPA and patients with mutated NPM1 without FLT3-ITD or with FLT3-
ITDlow. The ELN intermediate-risk category includes patients with wild-type or single-
mutated CEBPA, patients with wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow, and/
or patients with mutated NPM1 and FLT3-ITDhigh. The ELN adverse-risk category
comprises patients with wild-type or single-mutated CEBPA and wild-type NPM1 with
FLT3-ITDhigh, patients with mutated RUNX1 and/or ASXL1 (if these mutations do not co-
occur with favorable-risk subtypes), and/or patients with mutated TP53. FLT3-ITDlow is
defined by an FLT3-ITD/FLT3 wild-type allelic ratio of ,0.5, and FLT3-ITDhigh is defined by
an FLT3-ITD/FLT3 wild-type allelic ratio of equal to or more than 0.5.
‡The median expression value was used as a cut point.
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regulation of RNA biosynthesis (supplemental Table 20). Collec-
tively, these data show that circRNA expression, in addition to its
association with clinical outcome and prognostic mutations, also
has biologic significance in CN-AML.
Discussion
CircRNAs are a novel class of noncoding RNA molecules that are
gaining increasing recognition for their functional significance in
health and disease.21-25 Although circRNAs have previously been
reported to stem from chromosomal translocations that are
recurrent in AML and to be involved in malignant transformation,40
their prognostic and biologic significance in AML has not been
extensively studied.
In this work, we have profiled a large number of samples from CN-
AML patients using ribosomal RNA-depleted RNA-seq protocols to
capture RNA transcripts independent of polyadenylation status. Most
of the available RNA-seq data sets from AML patients have been
generated using polyadenosine tail-based selection, because this has
been shown to be the most cost-effective approach for the study of
protein-coding transcripts. In contrast to these data sets, our approach
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Figure 2. Clinical outcome of 111 younger adult patients with CN-AML in the validation set with either high or low expression of individual circRNAs. DFS (A),
OS (B), and EFS (C) of high vs low expressers of circKLHL8. DFS (D), OS (E), and EFS (F) of high vs low expressers of circSMC1A.
Table 3. Multivariable analyses for clinical outcome in the validation set of younger adult patients with CN-AML
Variable in final model
DFS OS EFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
circKLHL8, high vs low* 0.53 (0.30-0.91) .02 0.53 (0.32-0.88) .01 0.46 (0.28-0.76) .002
circFCHO2, high vs low* — — 0.45 (0.27-0.75) .002 0.56 (0.34-0.92) .02
FLT3-ITD, present vs absent 2.53 (1.46-4.39) ,.001 — — — —
DNMT3A, mutated vs wild type — — — — 1.93 (1.18-3.16) .009
MN1, high vs low* 2.23 (1.31-3.80) .003 2.63 (1.59-4.36) ,.001 2.15 (1.30-3.56) .003
Variables considered for model inclusion were: circKLHL8 (high vs low), circFCHO2 (high vs low), circCFLAR (high vs low), circSMC1A (high vs low), age (as a continuous variable, in
10-y increments), sex (male vs female), race (white vs nonwhite), white blood cell count (as a continuous variable, in 50-unit increments), hemoglobin (as a continuous variable, in 1-unit
increments), platelet count (as a continuous variable, in 50-unit increments), extramedullary involvement (present vs absent), ASXL1 mutations (mutated vs wild type), CEBPA mutations
(double mutated vs single mutated or wild type), DNMT3A mutations (mutated vs wild type), FLT3-ITD (present vs absent), FLT3-TKD (present vs absent), IDH1 mutations (mutated vs wild
type), IDH2 mutations (mutated vs wild type), NPM1 mutations (mutated vs wild type), RUNX1 mutations (mutated vs wild type), SF1 (mutated vs wild type), SF3A1 (mutated vs wild type),
SF3B1 (mutated vs wild type), SRSF2 (mutated vs wild type), TET2 mutations (mutated vs wild type), U2AF1 (mutated vs wild type), U2AF2 (mutated vs wild type), WT1 mutations (mutated
vs wild type), ZRSR2 (mutated vs wild type), ERG expression levels (high vs low), BAALC expression levels (high vs low), MN1 expression levels (high vs low), miR-181a expression levels
(high vs low), miR-3151 (expressed vs not expressed), and miR-155 expression levels (high vs low).
CI, confidence interval.
*The median expression value was used as the cut point.
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allows profiling of a wide variety of noncoding transcripts in
addition to mRNAs. Thus, the availability of whole-transcriptome
sequencing data of CN-AML patients with detailed clinical and
molecular information is an important step toward understanding
noncoding RNA biology and discovering novel biomarkers and
therapeutic targets.
We studied the expression of circRNAs and their association with
clinical features and outcome of patients with CN-AML and
performed experiments to investigate whether circRNAs are
functionally relevant in this disease. We developed a new algorithm
(MScircRNA) to detect and quantify circRNA transcripts from RNA-
seq. We further validated in vitro the performance of our pipeline by
conducting analysis on samples treated with RNase R, the gold-
standard method for identifying true circular transcripts. Altogether,
our results confirmed that MScircRNA is a reliable and sensitive
method for circRNA detection and quantification.
Global circRNA expression profiling classified CN-AML samples
of our data set into 3 groups, each with distinctive enrichment of
recurrent mutations and clinical features. By using a robust
training/validation approach, we identified 4 circRNAs that were
associated with outcome. In multivariable analyses, high expres-
sion of 2 of these circRNAs (circKLHL8 and circFCHO2) were
independently associated with EFS, DFS, and OS after adjusting for
other covariates.
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Figure 3. Functional significance of circRNA expression in AML. (A-B) Relative expression of linPCMTD1, circPCMTD1, linKLHL8, circKLHL8, linCFLAR, circCFLAR,
linFBXW7, and circFBXW7 in KG-1a (A) and OCI-AML3 (B) cells. (C-D) Circular-to-linear (circ/lin) ratio of the PCMTD1, KLHL8, CFLAR, and FBXW7 transcripts in mock vs
RNase R–treated samples of KG1a (C) and OCI-AML3 (D) cells. The log2 value of the circ/lin ratio is depicted in the figures. (E) Schematic description of the PCR experi-
ments with divergent primers. The reverse primer (primer A) binds to the 59 end of exon 1 and the forward primer (primer B) binds to the 39 end of exon 2. With this design,
amplicons can be generated after hybridization of the primers on circular RNA transcripts but not on genomic DNA. (F) circPCMTD1, circKLHL8, circCFLAR, and circFBXW7
PCR results using complementary DNA and genomic DNA of KG-1a cells. The integrity of the DNA was tested with primers specific for the ACTB DNA promoter region.
(G-H) Proliferation analyses of scramble vs circFBXW7 KD-treated KG-1a (G) and OCI-AML3 (H) cells, as measured by a colorimetric assay, based on degradation of the
WST1 reagent. (I-J) Proliferation analyses of scramble vs circFBXW7 KD-treated KG-1a (I) and OCI-AML3 (J) cells, based on BrdU incorporation. (K-M) Relative RNA expres-
sion of linFBXW7 and circFBXW7 in scramble vs circFBXW7 KD-treated KG-1a cells (K), OCI-AML3 cells (L), and AML patient blasts (M). (M) Samples of 1 patient are
depicted as an example. (N) Colony-forming unit assays in methylcellulose-based media with scramble vs circFBXW7 KD-treated AML patient blasts of 3 different patients.
N.S., not significant.
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Lastly, we conducted proof-of-principle experiments to evaluate the
biologic role of circRNAs in AML. We performed a small-scale KD
screening, focusing on 4 candidate circRNAs and using oligonu-
cleotides, which targeted the circRNAs without perturbing the
corresponding linear transcripts. Depletion of 1 of the candidate
circRNAs, circFBXW7, affected the phenotype of the AML cell lines
and primary AML samples that were tested and led to an increase in
their proliferative capacity. On the basis of the lack of miR binding
sites in circFBXW7, it is unlikely that these effects are mediated via
sequestration of miRs. Although more experiments will be needed
to understand how circFBXW7 regulates proliferation of the
leukemic blasts, our current data lend support to the functional
relevance of circRNA expression in AML.
In summary, we have performed the first comprehensive circRNA
profiling of a large CN-AML patient cohort. We identified distinctive
clusters of circRNA expression, which are associated with recurrent
mutations and clinical features of CN-AML patients. In addition, we
provide evidence that 1 of the analyzed circRNAs, circFBXW7, acts
as a tumor suppressor in AML.
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20. Rybak-Wolf A, Stottmeister C, Glažar P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol
Cell. 2015;58(5):870-885.
21. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333-338.
22. Holdt LM, Kohlmaier A, Teupser D. Molecular roles and function of circular RNAs in eukaryotic cells. Cell Mol Life Sci. 2018;75(6):1071-1098.
23. Armakola M, Higgins MJ, Figley MD, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet.
2012;44(12):1302-1309.
24. Greene J, Baird A-M, Brady L, et al. Circular RNAs: biogenesis, function and role in human diseases. Front Mol Biosci. 2017;4(4):38.
25. Yu C-Y, Li T-C, Wu Y-Y, et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat Commun. 2017;
8(1):1149.
26. Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat
Commun. 2016;7:11215.
27. Wei X, Li H, Yang J, et al. Circular RNA profiling reveals an abundant circLMO7 that regulates myoblasts differentiation and survival by sponging
miR-378a-3p. Cell Death Dis. 2017;8(10):e3153.
28. Li Y, Zheng F, Xiao X, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 2017;18(9):
1646-1659.
29. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453-461.
30. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15(7):409.
31. Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus [published correction appears in Nat Struct Mol Biol. 2017;
24(2):194]. Nat Struct Mol Biol. 2015;22(3):256-264.
32. Legnini I, Di Timoteo G, Rossi F, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis.Mol Cell. 2017;66(1):22-37.e9.
33. Pamudurti NR, Bartok O, Jens M, et al. Translation of circRNAs. Mol Cell. 2017;66(1):9-21.e7.
34. Abe N, Matsumoto K, Nishihara M, et al. Rolling circle translation of circular RNA in living human cells. Sci Rep. 2015;5:16435.
35. Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N6-methyladenosine. Cell Res. 2017;27(5):626-641.
36. Ng WL, Mohd Mohidin TB, Shukla K. Functional role of circular RNAs in cancer development and progression. RNA Biol. 2018;15(8):995-1005.
37. Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555-565.
38. Li Y, Zeng X, He J, et al. Circular RNA as a biomarker for cancer: a systematic meta-analysis. Oncol Lett. 2018;16(3):4078-4084.
39. Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and
CDK2. Nucleic Acids Res. 2016;44(6):2846-2858.
40. Guarnerio J, Bezzi M, Jeong JC, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations [published
correction appears in Cell. 2016;166(4):1055-1056]. Cell. 2016;165(2):289-302.
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